Entry |
|
Name |
First/second-generation tyrosine kinase inhibitor to EGFR mutation
|
Definition |
(Gefitinib,Erlotinib,Afatinib,Dacomitinib) -| EGFR* |
Expanded |
(D01977,D04023,D09733,D10514) -| 1956v2 |
Type |
Drug target
|
Gene |
1956 | EGFR; epidermal growth factor receptor |
|
Variant |
1956v2 EGFR mutation in non-small cell lung cancer
|
Perturbant |
D01977 | Gefitinib (first generation) |
D04023 | Erlotinib (first generation) |
D09733 | Afatinib (second generation) |
D10514 | Dacomitinib (second generation) |
|
Reference |
|
Authors |
Liao BC, Lin CC, Yang JC |
Title |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. |
Journal |
|
Reference |
|
Authors |
Sharma SV, Bell DW, Settleman J, Haber DA |
Title |
Epidermal growth factor receptor mutations in lung cancer. |
Journal |
|
LinkDB |
|